{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:38:04Z","timestamp":1768491484610,"version":"3.49.0"},"posted":{"date-parts":[[2020,5,20]]},"group-title":"Microbiology","reference-count":55,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an\n                  <jats:italic>in-situ<\/jats:italic>\n                  gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with preincubation of the virus with these PVP-I formulations at the lowest concentrations tested. It has been demonstrated that both PVP-I formulations can inactivate SARS-CoV-2 virus efficiently in both a dose-dependent and a time-dependent manner. These results suggest IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively. Further studies are needed to clinically evaluate these formulations in early-stage COVID-19 patients.\n                <\/jats:p>","DOI":"10.1101\/2020.05.18.103184","type":"posted-content","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T06:45:22Z","timestamp":1590043522000},"source":"Crossref","is-referenced-by-count":18,"title":["<i>In-Vivo<\/i>\n                  Toxicity Studies and\n                  <i>In-Vitro<\/i>\n                  Inactivation of SARS-CoV-2 by Povidone-iodine\n                  <i>In-situ<\/i>\n                  Gel Forming Formulations"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-4002","authenticated-orcid":false,"given":"Bo","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-7332","authenticated-orcid":false,"given":"Xudong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9600-0982","authenticated-orcid":false,"given":"Gang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhou","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Javer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Julander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Michail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024080405520488000_2020.05.18.103184v1.1","unstructured":"\u201cCoronavirus Disease 2019\u201d. World Health Organization. [Cited 2020 May 12]. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"2024080405520488000_2020.05.18.103184v1.2","unstructured":"\u201cWHO Director-General\u2019s opening remarks at the media briefing on COVID-19-11 March 2020\u201d. World Health Organization. 11 March 2020. [Cited 2020 May 12]. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.micinf.2020.01.004","article-title":"Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses","volume":"22","year":"2020","journal-title":"Microbes and Infection"},{"key":"2024080405520488000_2020.05.18.103184v1.4","unstructured":"\u201cStatement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)\u201d. World Health Organization. 30 January 2020. [Cited 2020 May 12] https:\/\/www.who.int\/news-room\/detail\/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)."},{"issue":"10223","key":"2024080405520488000_2020.05.18.103184v1.5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","year":"2020","journal-title":"The Lancet"},{"issue":"8","key":"2024080405520488000_2020.05.18.103184v1.6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJMe2001126","article-title":"Another Decade, Another Coronavirus","volume":"382","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"2024080405520488000_2020.05.18.103184v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0118-9"},{"key":"2024080405520488000_2020.05.18.103184v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.81"},{"issue":"1","key":"2024080405520488000_2020.05.18.103184v1.9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2013a review of immune changes in patients with viral pneumonia","volume":"9","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"2024080405520488000_2020.05.18.103184v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"2024080405520488000_2020.05.18.103184v1.11","unstructured":"\u201cQ&A on coronaviruses\u201d. World Health Organization. 11 February 2020. [Cited 2020 May 12]. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/question-and-answers-hub\/q-a-detail\/q-a-coronaviruses"},{"key":"2024080405520488000_2020.05.18.103184v1.12","unstructured":"\u201cQ & A on COVID-19\u201d. European Centre for Disease Prevention and Control. 24 April 2020 [Cited 2020 May 12]. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/questions-answers"},{"key":"2024080405520488000_2020.05.18.103184v1.13","unstructured":"\u201cCoronavirus Disease 2019 (COVID-19)\u2014Transmission\u201d. Centers for Disease Control and Prevention. 17 March 2020. [Cited 2020 May 12]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/prevent-getting-sick\/how-covidspreads.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Ftransmission.html"},{"key":"2024080405520488000_2020.05.18.103184v1.14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","year":"2020","journal-title":"Nature Medicine"},{"key":"2024080405520488000_2020.05.18.103184v1.15","doi-asserted-by":"crossref","unstructured":"Zhou L , Xua Z , Castiglionea GM , Soibermana US , Eberhart CG , Duh EJ. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. BioRxiv. May 9, 2020. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.09.086165v1","DOI":"10.1101\/2020.05.09.086165"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.15406\/aovs.2020.10.00382","article-title":"COVID-19: Ocular manifestations, ocular secretions, and ocular portal of entry","volume":"10","year":"2020","journal-title":"Adv Ophthalmol Vis Syst"},{"key":"2024080405520488000_2020.05.18.103184v1.17","first-page":"127","article-title":"Stabilized PVP-I Solutions","volume":"126","year":"1992","journal-title":"United States Patent #5"},{"key":"2024080405520488000_2020.05.18.103184v1.18","unstructured":"Liang B , Tessema B , Capriotti JA , Michael SC , Wei S. Pharmaceutical Compositions comprising iodine and steroid and uses thereof for sinus diseases. WO 2012\/177251 US 2014\/0219949. 2012 Dec 27."},{"issue":"10","key":"2024080405520488000_2020.05.18.103184v1.19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archotol.129.10.1098","article-title":"Evaluation of topical povidone-iodine in chronic suppurative otitis media","volume":"129","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"6","key":"2024080405520488000_2020.05.18.103184v1.20","first-page":"265","article-title":"NHG-standard otitis externa","volume":"28","year":"1995","journal-title":"Huisarts Wet"},{"issue":"468","key":"2024080405520488000_2020.05.18.103184v1.21","first-page":"533","article-title":"Otitis externa in UK general practice: a survey using the UK General Practice Research Database","volume":"51","year":"2001","journal-title":"Br J Gen Pract"},{"key":"2024080405520488000_2020.05.18.103184v1.22","unstructured":"Kavanagh K. Chronic Otitis Externa and Otomycosis. World Articles in Ear Nose & Throat. 27 May 2008. [Cited 2020 May 12] http:\/\/www.waent.org\/archives\/2008\/vol1\/chronic_otitis_externa\/otomycosis.htm"},{"key":"2024080405520488000_2020.05.18.103184v1.23","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200009000-00021"},{"issue":"9","key":"2024080405520488000_2020.05.18.103184v1.24","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.arth.2017.04.039","article-title":"Povidone-Iodine\u2013Based Solutions for Decolonization of Nasal Staphylococcus Aureus: A Randomized, Prospective, Placebo-Controlled Study","volume":"32","year":"2017","journal-title":"The Journal of Arthroplasty"},{"key":"2024080405520488000_2020.05.18.103184v1.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04624-14"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.26","first-page":"e6736","article-title":"Effectiveness of Preoperative Decolonization with Nasal Povidone Iodine in Chinese Patients Undergoing Elective Orthopedic Surgery: A Prospective Cross-Sectional Study","volume":"51","year":"2017","journal-title":"Braz J Med Biol Res"},{"key":"2024080405520488000_2020.05.18.103184v1.27","doi-asserted-by":"publisher","DOI":"10.1086\/676872"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000097758","article-title":"A Clinical Study on the Tolerability of a Liposomal Povidone-Iodine Nasal Spray: Implications for Further Development","volume":"69","year":"2007","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"2024080405520488000_2020.05.18.103184v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(98)90077-9"},{"issue":"11","key":"2024080405520488000_2020.05.18.103184v1.30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/ijcp.12707","article-title":"Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections","volume":"69","year":"2015","journal-title":"Int J Clin Pract"},{"key":"2024080405520488000_2020.05.18.103184v1.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-765X.2010.02871.x"},{"issue":"1","key":"2024080405520488000_2020.05.18.103184v1.32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4265\/bio.21.21","article-title":"Relationship between Virucidal Efficacy and Free Iodine Concentration of Povidone-Iodine in Buffer Solution","volume":"21","year":"2016","journal-title":"Biocontrol Sci"},{"issue":"1","key":"2024080405520488000_2020.05.18.103184v1.33","first-page":"119","article-title":"Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents","volume":"212","year":"2006","journal-title":"Dermatology"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40121-018-0200-7","article-title":"In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle\/Mouthwash Against Respiratory and Oral Tract Pathogens","volume":"7","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024080405520488000_2020.05.18.103184v1.35","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0091-9"},{"issue":"2","key":"2024080405520488000_2020.05.18.103184v1.36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40121-018-0202-5","article-title":"Bactericidal and Virucidal Activity of Povidone-Iodine and Chlorhexidine Gluconate Cleansers in an In Vivo Hand Hygiene Clinical Simulation Study","volume":"7","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2024080405520488000_2020.05.18.103184v1.37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1538\/expanim.61.35","article-title":"Evaluation of four antiseptics using a novel murine norovirus","volume":"61","year":"2012","journal-title":"Exp Anim"},{"key":"2024080405520488000_2020.05.18.103184v1.38","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1111-9"},{"key":"2024080405520488000_2020.05.18.103184v1.39","unstructured":"Kirk-Bayley J , Combes J , Sunkaraneni S , Challacombe S. The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Reduce Cross Infection and Protect Healthcare Workers. SSRN. https:\/\/ssrn.com\/abstract=3563092"},{"key":"2024080405520488000_2020.05.18.103184v1.40","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680606"},{"key":"2024080405520488000_2020.05.18.103184v1.41","unstructured":"Liang, B. , Baldwin J. , Wei G. Pharmaceutical Formulations that Form Gel In Situ. WO2017\/074965 and US2017\/0266294. 2017 April 5."},{"key":"2024080405520488000_2020.05.18.103184v1.42","unstructured":"Liang, B. In Situ Gel-Forming Pharmaceutical Compositions and Uses Thereof For Sinus Diseases. WO2019\/046844. 2019 July 3."},{"issue":"4","key":"2024080405520488000_2020.05.18.103184v1.43","first-page":"251","article-title":"In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin","volume":"53","year":"2003","journal-title":"Acta Pharm"},{"key":"2024080405520488000_2020.05.18.103184v1.44","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.012658"},{"key":"2024080405520488000_2020.05.18.103184v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70361-9"},{"key":"2024080405520488000_2020.05.18.103184v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"2024080405520488000_2020.05.18.103184v1.47","unstructured":"\u201cResearchers find two new drugs that can effectively inhibit coronavirus\u201d 4 February 2020. [Cited 2020 May 12]. https:\/\/news.cgtn.com\/news\/2020-02-04\/Researchers-find-two-drugs-that-can-effectively-inhibit-coronavirus-NOFpci7NJK\/index.html"},{"key":"2024080405520488000_2020.05.18.103184v1.48","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"issue":"13","key":"2024080405520488000_2020.05.18.103184v1.49","first-page":"213","article-title":"Medication for COVID-19-an Overview of Approaches Currently Under Study","volume":"117","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"2024080405520488000_2020.05.18.103184v1.50","doi-asserted-by":"crossref","unstructured":"Magro G. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies? Travel Med Infect Dis. 2020:101685.","DOI":"10.1016\/j.tmaid.2020.101685"},{"key":"2024080405520488000_2020.05.18.103184v1.51","unstructured":"Mehta N , Mazer-Amirshahi M , Alkindi N , Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020; http:https:\/\/www.ajemjournal.com\/article\/S0735-6757(20)30263-1\/pdf"},{"key":"2024080405520488000_2020.05.18.103184v1.52","doi-asserted-by":"crossref","unstructured":"Augustin M , Hallek M , Nitschmann S. Remdesivir in patients with severe COVID-19. Internist (Berl). 2020. https:\/\/link.springer.com\/article\/10.1007\/s00108-020-00800-5","DOI":"10.1007\/s00108-020-00800-5"},{"key":"2024080405520488000_2020.05.18.103184v1.53","unstructured":"Grein J , Ohmagari N , Shin D , Diaz G , Asperges E , Castagna A , et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2007016"},{"key":"2024080405520488000_2020.05.18.103184v1.54","unstructured":"Rae M , Claxon G , Kurani N , McDermott D , Cox C. Potential Costs of Coronavirus Treatment for People with Employer Coverage. Peterson-Kaiser Health System Tracker, 13 Mar. 2020. [Cited 2020 May 12]. www.healthsystemtracker.org\/brief\/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage\/"},{"key":"2024080405520488000_2020.05.18.103184v1.55","doi-asserted-by":"crossref","unstructured":"Lescure FX , Bouadma L , Nguyen D , Parisey M , Wickcy PH , Behillil S , et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases. 2020. https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(20)30200-0\/fulltext","DOI":"10.1016\/S1473-3099(20)30200-0"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.05.18.103184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:24:56Z","timestamp":1768436696000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2020.05.18.103184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1101\/2020.05.18.103184","relation":{},"subject":[],"published":{"date-parts":[[2020,5,20]]},"subtype":"preprint"}}